Evidence map›Paper›PMID 37490173›Full record

ArticleBreast cancer research and treatment2023

Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients.

Axel Muendlein, Christine Heinzle, Eva Maria Brandtner, Andreas Leiherer, Kathrin Geiger, Stella Gaenger, Heinz Drexel, Tobias Dechow, Thomas Decker

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Axel MuendleinVorarlberg Institute for Vascular Investigation and Treatment Laboratory, Stadtstrasse 33, 6850, Dornbirn, Austria. axel.muendlein@vivit.at.ORCID http://orcid.org/0000-0002-5582-4125
Christine HeinzleVorarlberg Institute for Vascular Investigation and Treatment Laboratory, Stadtstrasse 33, 6850, Dornbirn, Austria.
Eva Maria BrandtnerVorarlberg Institute for Vascular Investigation and Treatment Laboratory, Stadtstrasse 33, 6850, Dornbirn, Austria.
Andreas LeihererVorarlberg Institute for Vascular Investigation and Treatment Laboratory, Stadtstrasse 33, 6850, Dornbirn, Austria.
Kathrin GeigerVorarlberg Institute for Vascular Investigation and Treatment Laboratory, Stadtstrasse 33, 6850, Dornbirn, Austria.
Stella GaengerVorarlberg Institute for Vascular Investigation and Treatment Laboratory, Stadtstrasse 33, 6850, Dornbirn, Austria.
Heinz DrexelVorarlberg Institute for Vascular Investigation and Treatment Laboratory, Stadtstrasse 33, 6850, Dornbirn, Austria.
Tobias DechowOnkologie Ravensburg, Ravensburg, Germany.
Thomas DeckerOnkologie Ravensburg, Ravensburg, Germany.
Vorarlberg Institute for Vascular Investigation and Treatment · ATRavensburg University of Cooperative Education · DE

Funding

Interreg ABH055
6 · The paper itself

Abstract

purposeApolipoprotein M (APOM) is a plasma apolipoprotein closely involved with lipid metabolism and inflammation. In vitro studies suggest that APOM may also have a tumor-suppressive role in breast cancer. In the present study, we aimed to evaluate the impact of plasma APOM levels on the prognosis of breast cancer patients.

methodsWe measured APOM levels using an enzyme-linked immunosorbent assay in 75 patients with ER-positive/HER2-negative metastatic breast cancer. The endpoint was overall survival (OS) at 24 months.

resultsDuring the 24-month follow-up period, 34.7% of the patients died. Baseline APOM levels were significantly reduced in patients who deceased during follow-up compared to survivors (42.7 ± 14.5 µg/mL versus 52.2 ± 13.8 µg/mL; P = 0.003). Cox regression analysis showed a hazard ratio of 0.30 [95% confidence interval 0.15-0.61]; P < 0.001 per doubling of APOM levels. Correction for age, C-reactive protein, menopausal state, histology of the primary tumor, metastatic site, number of metastases, endocrine resistance, scheduled therapy line, and kind of scheduled therapy indicated that circulating APOM predicted OS independently of these parameters (HR

conclusionsOur study suggests that circulating APOM is significantly linked with reduced mortality in metastatic breast cancer patients.

Indexed as

Breast NeoplasmsApolipoproteinsApolipoproteins MEnzyme-Linked Immunosorbent AssayFemaleHumansMenopauseApolipoproteinsApolipoproteins MAPOM protein, humanApolipoprotein MBiomarkerMetastatic breast cancerPrognosis

Identifiers

PMID37490173
OpenAlexW4385230684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.